Although QX-314 did not affect cultured B16F10-mCherry-OVA cells or CD8+ T cell function in vitro (Extended Data Fig. 8a–f), we confirmed that it silences tumour-innervating nociceptors in vivo, as shown by reduced B16F10-induced release of CGRP and pain hypersensitivity (Extended Data Fig. 8g–i). This evidence concerns the gene CD8A and neoplasm.